Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review. (2nd July 2016)

• Record Type: Journal Article
• Authors: Bakker, Marina; Bunge, Eveline M.; Marano, Cinzia; de Ridder, Marc; De Moerlooze, Laurence
• Is Part Of: Expert review of vaccines. Volume 15:Number 7(2016)
• Page Start: 829
• Page End: 851
• Publication Date: 2016-07-02
• Subjects: Hepatitis A -- Hepatitis B -- Combined vaccine -- TwinrixTM -- AmbirixTM -- Immunogenicity -- Safety -- Effectiveness -- Efficacy; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1586/14760584.2016.1150182
• Languages: English
• ISSNs: 1476-0584

Abstract

ABSTRACT: Background : Hepatitis A and B are two of the most common vaccine-preventable diseases and vaccination for Hepatitis A virus (HAV) and hepatitis B virus (HBV) is recommended for those at risk of contracting HAV and/or HBV through their occupation, travel or lifestyle. Objective : To describe the vaccine efficacy, immunogenicity, effectiveness and safety of the combined vaccine against hepatitis A and hepatitis B. Methods : A systematic review of the literature published between 1990 and 2015. Results : Anti-HAV seropositivity rates ranged from 96.2% to 100% and anti-HBs seroprotection rates from 82% to 100%. Antibodies persisted up to 15 years and geometric mean concentration (GMC) remained above the seropositivity cut-off value for both. Anti-HAV and anti-HBs immune responses were lower in less immunocompetent individuals one month after completion of the immunization schedule. The safety profiles of Twinrix TM and monovalent hepatitis A and B vaccines were similar. Conclusion : The vaccine offers satisfactory long-term immunogenicity rates, expected duration of protection and safety profile similar to the monovalent hepatitis A or B vaccines.